ZIOPHARM Issues Statement Clarifying Speculation on

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
ZIOPHARM Issues Statement Clarifying Speculation on Financing Activity

BOSTON, July 20, 2016 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP ), due to recent developments, today issued the following statement clarifying market speculation regarding the Company’s financing activity: 

“The Company currently has no plans to access the capital markets in a securities offering. As it builds upon its broad and diverse set of cancer immunotherapy programs and platforms under development, ZIOPHARM will continue to manage its financial strategy in a way that is consistent with the best interests of its shareholders and the long-term value of the Company.” 

About ZIOPHARM Oncology, Inc.:

ZIOPHARM Oncology is a Boston, Massachusetts-based biotechnology company employing novel gene expression, control and cell technologies to deliver safe, effective and scalable cell- and viral-based therapies for the treatment of cancer. The Company's immuno-oncology programs, in collaboration with Intrexon Corporation (NYSE: XON ) and the MD Anderson Cancer Center, include chimeric antigen receptor T cell (CAR-T) and other adoptive cell-based approaches that use non-viral gene transfer methods for broad scalability. The Company is advancing programs in multiple stages of development together with Intrexon Corporation's RheoSwitch Therapeutic System® technology, a switch to turn on and off, and precisely modulate, gene expression in order to improve therapeutic index. The Company's pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies.

Forward-Looking Safe-Harbor Statement:

This press release contains certain forward-looking information about ZIOPHARM Oncology, Inc. that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as "may," "will," "could," "expects," "plans," "anticipates," and "believes." These statements include, but are not limited to, statements regarding the Company’s plans and expectations regarding its securities offerings, fundraising activities and financial strategy, the progress, timing and results of preclinical and clinical trials involving the Company's drug candidates, and the progress of the Company's research and development programs. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied by, the forward-looking statements. These risks and uncertainties include, but are not limited to: our ability to finance our operations and business initiatives and obtain funding for such activities, whether chimeric antigen receptor T cell (CAR T) approaches, Ad-RTS-hIL-12, TCR and NK cell-based therapies, or any of our other therapeutic candidates will advance further in the pre-clinical or clinical trials process and whether and when, if at all, they will receive final approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies and for which indications; whether chimeric antigen receptor T cell (CAR T) approaches, Ad-RTS-hIL-12, TCR and NK cell-based therapies, and our other therapeutic products will be successfully marketed if approved; the strength and enforceability of our intellectual property rights; competition from other pharmaceutical and biotechnology companies; and the other risk factors contained in our periodic and interim SEC reports filed from time to time with the Securities and Exchange Commission, including but not limited to, our Annual Report on Form 10-K for the fiscal year ended December 31, 2015, and our Quarterly Report for the quarter ended March 31, 2016. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.

Trademarks:

RheoSwitch Therapeutic System ® (RTS ® ) technology is a registered trademark of Intrexon Corporation.

Contact: Lori Ann Occhiogrosso ZIOPHARM Oncology, Inc. 617-259-1987 locchiogrosso@ziopharm.com David Pitts Argot Partners 212-600-1902 david@argotpartners.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

WHP Global's Japan Move: A Major Toy Market Play

Updated Category News Views 93

New Horizons for Toys"R"Us in Japan Well, folks, look who's back in the toy game with a vengeance! WHP Global is shaking hands with Pan Pacific International Holdings (PPIH) to breathe new life into Toys"R"Us across Japan. Now PPIH isn’t just any player. We're talking about Japan's fourth-largest retailer, helming giants like Don Quijote and aiming to crown itself as...

Continue Reading
AdMaven's Mave AI: Revolutionizing Campaign Management

Updated Category News Views 106

Taking the Tedious Out of Advertising You've got to love it when technology actually makes life easier, rather than more complicated. AdMaven's latest fancy toy, the AI assistant Mave, is promising just that. It's designed to take the heavy lifting off advertisers' shoulders, especially the day-to-day grind of tweaking ad settings and monitoring performance. If you've...

Continue Reading
Rock & Roll Hall of Fame's 2026 Induction Triumph

Updated Category News Views 158

A Night of Unstoppable Talent The Rock & Roll Hall of Fame's 2026 Induction Ceremony and boy, what a spectacle it was. Held on a lively Saturday night, November 14, in Los Angeles, it wasn't just an event; it was an electrifying testament to music's profound impact. With the grand ceremony kicking off at the historic city of stars, this year's induction turned the dial to...

Continue Reading
Amdocs Faces a Storm: Investor Alert as Legal Probe Begins

Updated Category News Views 35

Amdocs' Recent Crisis: What Investors Need to Know Lately, it seems Amdocs Limited (NASDAQ: DOX) has found itself knee-deep in a situation that could make seasoned investors cringe. November shone some harsh light on the company's operations, a move that’s attracted attention from Schall, Brown & Schwartz LLP (“SBS”), a name not exactly foreign to shareholder...

Continue Reading
Thread AI Joins Microsoft Pegasus: Big AI Leap

Updated Category News Views 13

Thread AI Leaps Ahead with Microsoft Partnership There's excitement in the air as Thread AI joins forces with Microsoft by entering the exclusive Pegasus Program. In the ever-evolving world of AI, making a splash this big doesn't happen every day. People in the tech alley are buzzing, and it looks like Thread AI is ready to rumble on a larger stage—much like a scrappy...

Continue Reading
Nasdaq Tumbles: AI Hardware Pulls Markets Down

Updated Category News Views 49

Wall Street's Slide Fueled by AI Nerves The markets got a real jolt on Monday, sending Nasdaq down 2.5% thanks to a sharp dip in AI hardware stocks. Tech tickers tied to artificial intelligence were at the core of a sell-off, knocking the S&P 500 down 1.92% alongside it. Investors are on edge, and it’s not just the weather—it's a real shake-up driven by policy moves...

Continue Reading
Gwen Stefani Kicks Off OCVIBE's New Concert Hall

Updated Category News Views 199

A Homecoming Steeped in Nostalgia Orange County’s about to do a serious throwback, folks! Gwen Stefani is set to headline the opening concert at OCVIBE's spanking new concert hall in Anaheim on March 17, 2027. Curious choice for their opener? Hardly. This gal's practically woven into the county’s tapestry—her roots run deep here, enough to make even the casual music...

Continue Reading
Engrain's Geospatial Innovation Pushes Property Mapping Forward

Updated Category News Views 118

Pushing the Boundaries of Property Mapping How far can you expand the boundaries of property mapping tech? Well, Engrain seems hell-bent on finding out by cranking their innovations up a notch. The Denver-based stalwart in interactive mapping is rolling out some mind-boggling enhancements that could redefine how the multifamily housing sector operates. This isn't just...

Continue Reading
Gold Tumbles: Kinross Faces Class Action Lawsuit

Updated Category News Views 120

Digging Deep into Kinross's Legal Fallout Well, here's a doozy for those investing in the precious metal market. Kinross Gold Corporation (NYSE: KGC) finds itself knee-deep in legal muck. Investors who bought into the Canadian gold miner's promises might be scrambling, as a class action lawsuit has just been lobbed their way. The culprit? A hefty drop-off in their...

Continue Reading
Fluence Energy Faces Heat: Class Action Lawsuit Unfolds

Updated Category News Views 73

Fluence Energy's Difficult Waters Investors in Fluence Energy (NASDAQ: FLNC) are having a moment of reckoning, no doubt. November 2nd saw a nearly 9% drop in FLNC stock, further fueled by the sudden departures of the CEO and CFO just days earlier. This marks a bitter chapter for Fluence as its stock continues to bleed, leaving many wondering what seismic shifts are yet to...

Continue Reading

Top 5 Most Recently Viewed Articles

Trump's Tariff Threats Spark Global Market Reactions

Updated Category News Views 163

Market Reactions to Tariff Developments As global markets navigate uncertain waters today, optimism and anxiety intertwine. The US dollar has taken a slight step higher, while gold has seen a dip, all stemming from ongoing trade tensions and recent tariff announcements by President Trump. With negotiations that are seen as promising but fraught with complexities, the...

Continue Reading
Sutro Biopharma's Upcoming Presentation at J.P. Morgan Event

Updated Category News Views 228

Sutro Biopharma's Upcoming Conference Presentation Sutro Biopharma, Inc. (NASDAQ: STRO), a trailblazer in oncology therapies based in South San Francisco, has some exciting news. The company announced that its Chief Executive Officer, Bill Newell, will be presenting at the prestigious J.P. Morgan Healthcare Conference. This annual event is a pivotal opportunity for...

Continue Reading
Nightly Launches Ambitious $25 Million Experience Initiative

Updated Category News Views 302

Nightly Introduces a $25 Million Initiative In a bold move to reshape the live entertainment landscape, Nightly has announced a substantial $25 million initiative aimed at expanding its dynamic experiences across the nation. Originating from Dallas, Nightly has quickly evolved into a cultural movement that seeks to redefine nightlife specifically for Gen Z audiences. This...

Continue Reading
Tecan Announces 2024 Results, Focuses on Growth and Innovation

Updated Category News Views 609

Tecan Reports 2024 Financial Results Amid Market Challenges Overview of Financial Highlights Tecan has unveiled its financial results for 2024, showcasing a robust commitment to enhancing operational resilience in a challenging market environment. Sales figures totaled CHF 934.3 million, marking a decline from the previous year's CHF 1,074.4 million. This 13.0% drop in...

Continue Reading
Auddia, Inc. (AUUD) Merger: Shareholder Alert and Investigation Insights

Updated Category News Views 227

Auddia, Inc. (NASDAQ: AUUD) is under the microscope after news broke about its proposed merger with McCarthy Finney, Inc., which sent shockwaves through trader desks and shareholder circles alike. The date was February 18, 2026, when class action attorney Juan Monteverde announced an investigation into the deal that’s left many scratching their heads about whether this...

Continue Reading